Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Aurora A Inhibitor TAS-119 Enhances Antitumor Efficacy of Taxanes In Vitro and In Vivo: Preclinical Studies as Guidance for Clinical Development and Trial Design

Hiroshi Sootome, Akihiro Miura, Norio Masuko, Takamasa Suzuki, Yoshihiro Uto, Hiroshi Hirai

Mol Cancer Ther (2020) 19 (10): 1981–1991.

https://doi.org/10.1158/1535-7163.MCT-20-0036

Published: 02 October 2020

View article titled, Aurora A Inhibitor TAS-119 Enhances Antitumor Efficacy of Taxanes In Vitro and In Vivo: Preclinical Studies as Guidance for Clinical Development and Trial Design

Includes: Supplementary data

Journal Articles

Abstract C187: Cross-inhibition of Trk receptors by TAS-119, a novel Aurora A selective inhibitor, exhibits therapeutic potential in a Trk-driven cancer model

Hiroshi Sootome, Akihiro Miura, Kimihiro Ito, Takamasa Suzuki, Hiroshi Hirai, Teruhiro Utsugi, Kazuhiko Yonekura

Mol Cancer Ther (2015) 14 (12_Supplement_2): C187.

https://doi.org/10.1158/1535-7163.TARG-15-C187

Published: 01 December 2015

View article titled, Abstract C187: Cross-inhibition of Trk receptors by TAS-119, a novel Aurora A selective inhibitor, exhibits therapeutic potential in a Trk-driven cancer model

Journal Articles

Abstract A272: Intermittent treatment with TAS-120, an irreversible FGFR inhibitor, is effective in tumors harboring a FGFR gene abnormality.

Yoko Nakatsuru, Hiroaki Ochiiwa, Hiroshi Sootome, Hidenori Fujita, Akihiro Hashimoto, Yoshihiro Shibata, Masato Chiba, Yayoi Fujioka, Kazuhiro Yonekura, Hiroshi Hirai, Teruhiro Utsugi

Mol Cancer Ther (2013) 12 (11_Supplement): A272.

https://doi.org/10.1158/1535-7163.TARG-13-A272

Published: 01 November 2013

View article titled, Abstract A272: Intermittent treatment with TAS-120, an irreversible FGFR inhibitor, is effective in tumors harboring a FGFR gene abnormality.

Journal Articles

Abstract A271: TAS-120, an irreversible FGFR inhibitor, was effective in tumors harboring FGFR mutations, refractory or resistant to ATP competitive inhibitors .

Hiroshi Sootome, Yayoi Fujioka, Akihiro Miura, Hidenori Fujita, Hiroshi Hirai, Teruhiro Utsugi

Mol Cancer Ther (2013) 12 (11_Supplement): A271.

https://doi.org/10.1158/1535-7163.TARG-13-A271

Published: 01 November 2013

View article titled, Abstract A271: TAS-120, an irreversible FGFR inhibitor, was effective in tumors harboring FGFR mutations, refractory or resistant to ATP competitive inhibitors .

Journal Articles

Abstract A269: A selective Aurora A inhibitor, TAS-119, enhanced the antitumor activity of taxanes in an intermittent dosing schedule without affecting neurotoxicity.

Keiko Ishihara, Hiroshi Sootome, Takamasa Suzuki, Norio Masuko, Akihiro Miura, Megumu Okada, Nobuyuki Oda, Hiroshi Hirai, Teruhiro Utsugi

Mol Cancer Ther (2013) 12 (11_Supplement): A269.

https://doi.org/10.1158/1535-7163.TARG-13-A269

Published: 01 November 2013

View article titled, Abstract A269: A selective Aurora A inhibitor, TAS-119, enhanced the antitumor activity of taxanes in an intermittent dosing schedule without affecting neurotoxicity.

Journal Articles

Abstract A268: TAS-119, a selective Aurora A inhibitor, enhanced the antitumor efficacy of taxanes in multiple human tumor cell lines including paclitaxel-resistant cells.

Akihiro Miura, Hiroshi Sootome, Keiko Ishihara, Norio Masuko, Hiroshi Hirai, Teruhiro Utsugi

Mol Cancer Ther (2013) 12 (11_Supplement): A268.

https://doi.org/10.1158/1535-7163.TARG-13-A268

Published: 01 November 2013

View article titled, Abstract A268: TAS-119, a selective Aurora A inhibitor, enhanced the antitumor efficacy of taxanes in multiple human tumor cell lines including paclitaxel-resistant cells.

Journal Articles

Abstract A270: TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities.

Hiroaki Ochiiwa, Hidenori Fujita, Kimihiro Itoh, Hiroshi Sootome, Akihiro Hashimoto, Yayoi Fujioka, Yoko Nakatsuru, Nobuyuki Oda, Kazuhiko Yonekura, Hiroshi Hirai, Teruhiro Utsugi

Mol Cancer Ther (2013) 12 (11_Supplement): A270.

https://doi.org/10.1158/1535-7163.TARG-13-A270

Published: 01 November 2013

View article titled, Abstract A270: TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities.

Journal Articles

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

Hiroshi Hirai, Hiroshi Sootome, Yoko Nakatsuru, Katsuyoshi Miyama, Shunsuke Taguchi, Kyoko Tsujioka, Yoko Ueno, Harold Hatch, Pradip K. Majumder, Bo-Sheng Pan, Hidehito Kotani

Mol Cancer Ther (2010) 9 (7): 1956–1967.

https://doi.org/10.1158/1535-7163.MCT-09-1012

Published: 07 July 2010

View article titled, MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

Includes: Supplementary data

Journal Articles

Abstract A251: MK‐1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions in pancreatic tumor xenografts

N.V. Rajeshkumar, Elizabeth De Oliveira, Niki A. Ottenhof, Ignacio Garrido‐Laguna, Maria C. Villarroel, James Watters, Tim Demuth, David Brooks, Shinji Mizuarai, Hiroshi Hirai, Anirban Maitra, Manuel Hidalgo

Mol Cancer Ther (2009) 8 (12_Supplement): A251.

https://doi.org/10.1158/1535-7163.TARG-09-A251

Published: 10 December 2009

View article titled, Abstract A251: MK‐1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions in pancreatic tumor xenografts

Journal Articles

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

Mol Cancer Ther (2009) 8 (11): 2992–3000.

https://doi.org/10.1158/1535-7163.MCT-09-0463

Published: 10 November 2009

View article titled, Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

Includes: Supplementary data

Journal Articles

Expression levels of p18^INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines

Tomohiro Eguchi, Hiraku Itadani, Toshiyasu Shimomura, Nobuhiko Kawanishi, Hiroshi Hirai, Hidehito Kotani

Mol Cancer Ther (2009) 8 (6): 1460–1472.

https://doi.org/10.1158/1535-7163.MCT-08-1159

Published: 10 June 2009

View article titled, Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines

Includes: Supplementary data

NARROW

Aurora A Inhibitor TAS-119 Enhances Antitumor Efficacy of Taxanes In Vitro and In Vivo: Preclinical Studies as Guidance for Clinical Development and Trial Design

Abstract C187: Cross-inhibition of Trk receptors by TAS-119, a novel Aurora A selective inhibitor, exhibits therapeutic potential in a Trk-driven cancer model

Abstract A272: Intermittent treatment with TAS-120, an irreversible FGFR inhibitor, is effective in tumors harboring a FGFR gene abnormality.

Abstract A271: TAS-120, an irreversible FGFR inhibitor, was effective in tumors harboring FGFR mutations, refractory or resistant to ATP competitive inhibitors .

Abstract A269: A selective Aurora A inhibitor, TAS-119, enhanced the antitumor activity of taxanes in an intermittent dosing schedule without affecting neurotoxicity.

Abstract A268: TAS-119, a selective Aurora A inhibitor, enhanced the antitumor efficacy of taxanes in multiple human tumor cell lines including paclitaxel-resistant cells.

Abstract A270: TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities.

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

Abstract A251: MK‐1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions in pancreatic tumor xenografts

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

Expression levels of p18^INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only